Brought to you by 
Gardedam Therapeutics gets public listing, changes name after merger with Canadian shell
08 Jun 2022
Executive Summary
As a vehicle to go public, Gardedam Therapeutics Inc. (chaperone therapeutics for neurodegenerative diseases) is acquiring public Canadian shell company Lion Consulting Group Inc. through a reverse merger. The combined company changed its name to Cantabio Pharmaceuticals Inc., which will now operate under that name and trade on the OTC exchange under the symbol CTBO.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gardedam Therapeutics gets public listing, changes name after merger with Canadian shell
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice